Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
-

-

-
-
-
-
 
WKN: A12GT3 / Name: Indivior / Stock / Pharmaceuticals / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Indivior plc ADR Stock

Pros and Cons of Indivior plc ADR in the next few years

Pros
?
C******** o* t** e**********
?
M***** P*******
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

News

Why One Value Fund Has a $101 Million Bet on Indivior Stock Amid a 212% Surge: https://cdn.content.foolcdn.com/images/1umn9qeh/production/34d887ed4212e8f7cd62f3cec35549f0cf9a39c0-1401x1251.png?w=1401&h=1251
Why One Value Fund Has a $101 Million Bet on Indivior Stock Amid a 212% Surge

New York City-based Newtyn Management reported a buy of nearly 1.6 million additional Indivior PLC shares, increasing its position by an estimated $62.8 million in the third quarter, according to a

Here's Why Indivior Stock Soared 15% Today: https://g.foolcdn.com/editorial/images/840491/successful-investor.jpg
Here's Why Indivior Stock Soared 15% Today

Shares in Indivior Plc (NASDAQ: INDV) were up by 15.5% at 1 p.m. ET today after management released an excellent set of third-quarter results, upgraded its full-year guidance, and served notice that

Indivior (INDV) Q2 EPS Jumps 104%
Indivior (INDV) Q2 EPS Jumps 104%

Indivior (NASDAQ:INDV), a global pharmaceutical company known for its treatments for opioid use disorder (OUD), reported results on July 31, 2025. The main news was a sharp outperformance compared